Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1076 participants.
Also called NCT05968430
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,076 participants
- Sponsor
- Registry
-
NCT05968430
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- United States, Australia, Bulgaria, Canada, France, Germany, Italy, Netherlands, Poland, Puerto Rico, Romania, Spain, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05968430. Non-randomized; no masking; primary purpose treatment. Start 2023-07-14 (actual); primary completion 2025-12-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
- Condition
- Hypertension
- Intervention (Drug)
- lorundrostat
- Intervention (Drug)
- Placebo
- Lead sponsor
- Mineralys Therapeutics Inc.
Record details
- Record id
cardio:ct-nct05968430- Content hash
01fbdc88ec17842882d10b15ffe1c77f8bf79d3809803220bb31abd25bf86f42